Eicosapentaenoic Acid Ethyl Ester
Depression
National Center for Complementary and Integrative Health (NCCIH)Small moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 73/ 100
Competitive context
73 Active assets in the Depression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
S-Ketamine Chinese PLA General Hospital | Phase 4 | BBB |
VENLOR Janssen Research & Development, LLC | Phase 4 | BBB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE VA Office of Research and Development | Phase 4 | BBB |
FLUOXETINE University of Oxford | Phase 4 | BBB |
Cipralex Poznan University of Medical Sciences | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Eicosapentaenoic Acid Ethyl Ester is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →